# Chemical profile of Ficus lyrata bark extract and its therapeutic effect on non-alcoholic fatty liver disease via regulating oxidative stress, inflammation and hepatic lipogenesis

## TL;DR

This study shows that Ficus lyrata bark extract can help treat non-alcoholic fatty liver disease in rats by reducing liver damage and inflammation.

## Contribution

The novel contribution is the identification of Ficus lyrata bark extract as a potential therapeutic agent for NAFLD through its effects on oxidative stress and lipogenesis.

## Key findings

- Ficus lyrata extract reduced hyperglycemia, hyperinsulinemia, and aminotransferases in NAFLD rats.
- The extract downregulated hepatic lipogenic genes and inflammatory markers in the liver.
- Polyphenolic compounds in the extract showed good binding affinity to PPAR-γ and LXR-α receptors.

## Abstract

The high prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide necessitates the attention and intervention of modern medical treatment options. Preliminary studies have demonstrated that Ficus Lyrata leaves can exert protective effects in rats against hepatic fibrosis and hypercholesterolemia. Hence, this study was conducted to investigate the therapeutic effect of Ficus lyrata Wrab bark extract on the NAFLD rat model. NAFLD was induced through a high-fat diet (HFD) for 12 weeks in male Wistar rats. After four weeks of HFD feeding, the rats were treated with F. lyrata extract (250 mg/kg, 5 days/week) or simvastatin (4 mg/kg, 5 days/week) while continuing on the HFD till the end of the experiment. Serum and liver samples were harvested for biochemical, molecular, histopathological, and immunohistochemical investigations. In silico analysis was also conducted to analyse the binding affinity of the extract polyphenols and the key regulators of hepatic lipogenesis. The results revealed that F. lyrata extract administered to HFD-fed rats significantly improved the characteristics of NAFLD by reducing hyperglycemia, hyperinsulinemia, and aminotransferases while improving serum lipid profile and adipokines. Moreover, the extract reduced the expression of hepatic lipogenic genes sterol regulatory element-binding protein-1c (SREBP-1c), acetyl-CoA carboxylase-1 (ACC-1), and fatty acid synthase (FAS), and inflammatory markers tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6), along with modulating oxidative stress markers and reversing histopathological changes. Molecular docking study revealed that most polyphenolic compounds in F. lyrata extract exhibited good binding affinity towards peroxisome proliferator-activated receptors γ (PPAR-γ) and liver X receptor α (LXR-α). In conclusion, our findings suggested that F. lyrata bark could be a promising therapeutic agent against the health issues related to NAFLD.